No connection

Search Results

CLLS

BEARISH
$3.36 Live
Cellectis S.A. · NASDAQ
Target $7.25 (+115.8%)
$1.17 52W Range $5.48

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 08, 2026
Market cap
$337.99M
P/E
N/A
ROE
-65.3%
Profit margin
-84.9%
Debt/Equity
1.14
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
45%
CLLS shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.

Key Strengths

Company has established market presence

Key Risks

Low profit margin of -84.9%
Weak financial trend (Piotroski F-Score: 1/9)
Declining revenue (-19.5%)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
29
Weak
Value
50
Future
35
Past
30
Health
30
Dividend
0
AI Verdict
CLLS shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Low profit margin of -84.9%, Weak financial trend (Piotroski F-Score: 1/9)
Confidence
5%
Value
50/100

Rule-based valuation (P/E + Graham).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
35/100

Rule-based growth outlook.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • Revenue is contracting.
Past
30/100

Historical performance + price trend: Shares moved -83.4% over 5Y and +189.7% over 1Y.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • ROE only -65.3%.
  • Thin profit margins.
Health
30/100

Balance sheet & liquidity (Z-Score: N/A).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Dividend policy fallback.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • No regular dividend payments.

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$3.36
Analyst Target
$7.25
Upside/Downside
+115.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for CLLS and closest competitors.

Updated 2026-04-07
CLL
Cellectis S.A.
Primary
5Y
-83.4%
3Y
+71.4%
1Y
+189.7%
6M
-12.0%
1M
-6.7%
1W
+6.0%
AMR
Amarin Corporation plc
Peer
5Y
-88.3%
3Y
-51.5%
1Y
+87.1%
6M
+2.2%
1M
+1.5%
1W
+9.1%
ACI
AC Immune SA
Peer
5Y
-62.7%
3Y
+31.1%
1Y
+31.1%
6M
+24.1%
1M
-0.5%
1W
+8.1%
BNR
Burning Rock Biotech Limited
Peer
5Y
-89.9%
3Y
+6.9%
1Y
+414.2%
6M
+415.7%
1M
+65.3%
1W
+9.6%
ANL
Adlai Nortye Ltd.
Peer
5Y
-47.0%
3Y
-47.0%
1Y
+247.2%
6M
+345.4%
1M
-14.4%
1W
-10.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-5.42
PEG Ratio
N/A
P/B Ratio
3.2
P/S Ratio
4.25
EV/Revenue
1.63
EV/EBITDA
-5.98
Market Cap
$337.99M

Profitability

Profit margins and return metrics

Profit Margin -84.92%
Operating Margin -142.14%
Gross Margin 100.0%
ROE -65.33%
ROA -5.84%

Growth

Revenue and earnings growth rates

Revenue Growth -19.5%
Earnings Growth N/A
Q/Q Revenue Growth -18.25%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
1.14
Moderate
Current Ratio
1.62
Good
Quick Ratio
1.59
Excellent
Cash/Share
$2.84

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
71.2%
Op. Margin
-166.9%
Net Margin
-253.2%
Total Assets
$0.3B
Liabilities
$0.2B
Equity
$0.1B
Debt/Equity
3.28x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
105%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-18
$N/A
2026-03-19
$-0.24
-140.0% surprise
2025-11-07
$0.02
+120.0% surprise
2025-08-04
$-0.22
-46.7% surprise

Healthcare Sector Comparison

Comparing CLLS against 162 companies in the Healthcare sector (15 bullish, 52 neutral, 95 bearish)
Return on Equity (ROE)
-65.33%
This Stock
vs
-42.35%
Sector Avg
+54.2% (Excellent)
Profit Margin
-84.92%
This Stock
vs
-18.25%
Sector Avg
+365.5% (Superior)
Debt to Equity
1.14
This Stock
vs
5.74
Sector Avg
-80.1% (Less Debt)
Revenue Growth
-19.5%
This Stock
vs
114.26%
Sector Avg
-117.1% (Slower)
Current Ratio
1.62
This Stock
vs
3.36
Sector Avg
-51.7% (Weaker)

Similar Companies

Peer comparison within the same industry

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
4 analysts
Clear Street
2025-12-23
init
Buy
Barclays
2025-10-17
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning CLLS from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile